What is it about?

Studies presented in patents show that venetoclax might be useful in aditional therapeutic indications. Venetoclax is a chemotherapeutic used for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). Venetoclax shows promise in combinational treatment against multiple types of cancer that are otherwise not responsive to single agents from said combinations.

Featured Image

Why is it important?

The review offers a broad overview of the therapetic applications of venetoclax and Bcl-2 inhibitors in general. It shows the potential treatment options for various indiacations as well as points to relevant patent (and other) literature. Expert opinion points to future perspectives in the field.

Perspectives

Patent literature can sometimes be a hard read, especially to people not too familiar with it. I hope this article can help people find new information about this novel chemotherapetic and drive to some exciting research.

Nina Žigart
Faculty of Pharmacy, University of Ljubljana

Read the Original

This page is a summary of: A literature review of the patent publications on venetoclax – a selective Bcl-2 inhibitor: discovering the therapeutic potential of a novel chemotherapeutic agent, Expert Opinion on Therapeutic Patents, June 2019, Taylor & Francis, DOI: 10.1080/13543776.2019.1627327.
You can read the full text:

Read

Contributors

The following have contributed to this page